Protalix BioTherapeutics (PLX) Invested Capital (2016 - 2025)
Historic Invested Capital for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $52.9 million.
- Protalix BioTherapeutics' Invested Capital rose 6311.0% to $52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 6311.0%. This contributed to the annual value of $43.2 million for FY2024, which is 1971.2% down from last year.
- As of Q3 2025, Protalix BioTherapeutics' Invested Capital stood at $52.9 million, which was up 6311.0% from $49.9 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Invested Capital registered a high of $69.9 million during Q1 2021, and its lowest value of -$11.5 million during Q3 2022.
- Its 5-year average for Invested Capital is $29.6 million, with a median of $43.2 million in 2024.
- In the last 5 years, Protalix BioTherapeutics' Invested Capital tumbled by 43354.58% in 2022 and then skyrocketed by 488075.4% in 2024.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Invested Capital stood at -$6.0 million in 2021, then plummeted by 76.28% to -$10.6 million in 2022, then soared by 605.83% to $53.8 million in 2023, then dropped by 19.71% to $43.2 million in 2024, then increased by 22.44% to $52.9 million in 2025.
- Its Invested Capital stands at $52.9 million for Q3 2025, versus $49.9 million for Q2 2025 and $45.2 million for Q1 2025.